DUETTE: A randomized phase II study to assess a second maintenance treatment with olaparib (ola) or ola+ceralasertib (cer), in patients (pts) with platinum-sensitive relapsed (PSR) epithelial ovarian cancer who have previously received PARP inhibitor maintenance treatment (NCT04239014).

Amit M. Oza,Andrew Pierce,Alan Lau,Nisha Kurian,Graeme Parr,Si-Houy Lao-Sirieix,Mei Lin W. Ah-See,Emma Dean,Bienvenu Loembé

DUETTE: A randomized phase II study to assess a second maintenance treatment with olaparib (ola) or ola+ceralasertib (cer), in patients (pts) with platinum-sensitive relapsed (PSR) epithelial ovarian cancer who have previously received PARP inhibitor maintenance treatment (NCT04239014).

2020

Amit M. Oza
Andrew Pierce
Alan Lau
Nisha Kurian
Graeme Parr
Si-Houy Lao-Sirieix
Mei Lin W. Ah-See
Emma Dean
Bienvenu Loembé

TPS6104Background: Ovarian cancer is the leading cause of death from gynecological cancers in the USA, and the fifth most common cause of cancer death in women. Ola is a PARPi approved for first-li...

Keywords:

Oncology
Olaparib
in patient
epithelial ovarian cancer
Phases of clinical research
PARP inhibitor
Pathology
platinum sensitive
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations